Status:

COMPLETED

Acupuncture/Moxibustion for Peripheral Neuropathy in HIV

Lead Sponsor:

National Center for Complementary and Integrative Health (NCCIH)

Conditions:

Peripheral Neuropathies

HIV Infections

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

This is a sample-size-limited, randomized, blinded (subject and evaluator), sham acupuncture/placebo moxibustion (sham acu/placebo moxa) controlled clinical trial. The subjects in this study will be 5...

Detailed Description

Subjects in this early-phase clinical trial will be 50 men and women with HIV infection who have a diagnosis of Distal Symmetric Peripheral neuropathy (DSP). This study is a prospective, randomized, s...

Eligibility Criteria

Inclusion

  • Men and women who are HIV positive or Centers for Disease Control (CDC)-defined AIDS diagnosed subjects who are 18 years of age or older, and have a history of distal symmetrical peripheral neuropathy of the lower extremities (legs and feet) for two months or greater.
  • Patients experiencing moderate pain severity.
  • Verification from primary provider of subject's: HIV status, diagnosis of DSP, and agreement that patient is clinically suitable for the study.
  • Individuals able to successfully complete a mini-mental status exam.
  • Individuals who understand and agree to complete daily symptom diaries for the duration of the study.
  • Individuals taking antiretroviral combinations must have completed an initial 8 weeks of a stable regime (same drug\[s\], dose, and frequency) prior to entry into the study.
  • Individuals taking chronic pain medications must be on a stable regime (same drug, dose, and frequency) for at least twenty-one (21) days prior to entry into the study.
  • Individuals on all other medications which may have neuropathy listed as a side effect must be on a stable regime (same drug\[s\], dose, and frequency) for at least 21 days prior to entry in the study.

Exclusion

  • Individuals with an acute medical condition, i.e. pneumocystis carinii pneumonia, tuberculosis, and/or other opportunistic infections or conditions that would require medical attention.
  • Individuals with diagnosis of diabetes mellitus, B-12 deficiency
  • Topically applied medications to the lower extremities.
  • Individuals with alcohol and/or substance dependence.
  • Individuals with bleeding tendency
  • Currently receiving treatment with corticosteroids
  • Use of isoniazid (INH), dapsone, or metronidazole within 8 weeks prior to enrollment.
  • Severe heart disease, uncontrolled high blood pressure, lung disease, or renal failure.
  • Pregnant women
  • Individuals receiving acupuncture currently and less than 6 months prior to enrollment.
  • Individuals with a history of receiving moxibustion.
  • Individuals currently receiving other types of complementary therapies such as herbs, massage, reiki, etc.
  • Individuals with plans for travel, lifestyle change, or other activity that would preclude attending all of the planned study sessions and/or recording daily diary information.

Key Trial Info

Start Date :

November 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2009

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT00317291

Start Date

November 1 2005

End Date

January 1 2009

Last Update

September 11 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Columbia University School of Nursing, Acupuncture Laboratory

New York, New York, United States, 10032

Acupuncture/Moxibustion for Peripheral Neuropathy in HIV | DecenTrialz